Amgen has successfully fought off Novartis’ Enbrel biosimilar, Erelzi, following a U.S. Federal Appeals Court decision that upheld an earlier ruling in favor of Amgen’s intellectual property. Novartis is considering a further appeal to the U.S. Supreme Court. For the treatment of rheumatoid arthritis under the pharmacy benefit, Enbrel currently holds preferred status for just 5% of covered lives, but this grows to 48% after prior authorization and/or step therapy. Enbrel is classified as a specialty drug for 27% of covered lives.

SOURCE: MMIT Analytics, as of 7/8/20